{
  "docId": "019de075-8a55-750a-8008-603750933d71",
  "docSlug": "da8608bdf4ad385699d1340db7dce185",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 56,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Swimmer plot visualization of clinical trial data (Trial LXH254X2102).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/18",
  "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
  "deckJsonHref": "/decks/019de075-8a55-750a-8008-603750933d71.json",
  "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.67,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Responses observed in patients with normal or high LDH. Median DOR was 3.75 months. Median PFS was 5.5 months.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9db1c7a4-2f0c-41c9-b5c3-d14a743a9a7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.03,
        "y": 0.165
      },
      "kind": "chart",
      "text": "Duration of Exposure",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17fd7627-4c4e-47d2-a348-a8c7eb35bafc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.02,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "De Braud et al AACR 2022 (Trial LXH254X2102, NCT02974725) * Median PFS was calculated based on patients enrolled on the napo 200mg BID + trame 1.0mg QD dose",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdf67f01-5dc1-41d7-afb1-bc0d23877349",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.67,
        "y": 0.54
      },
      "kind": "legend",
      "text": "Response: CR, PR, Non-CR/Non-PD, SD, PD, UNK. Treatment: Naporafenib 200 mg BID + trametinib 1.0 mg QD",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2f33f86-f115-48c2-bbd2-3056b0ffe73c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Phase 1 in NRASm melanoma: naporafenib and trametinib exhibited durable time on treatment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b59f8bd2-4957-4bca-b4aa-9f8770021100",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 15,
      "beatId": "0ba8dc28-f394-4539-9ceb-99555f1271c2",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document highlights the unmet needs and limitations of current treatments for NRASm metastatic melanoma.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    },
    {
      "to": 20,
      "from": 13,
      "beatId": "f286216e-8f02-4c67-ba26-139ada264780",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document provides evidence and proof of Erasca's pipeline and its potential effectiveness.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1dd29138-5e83-440f-a4ea-0cd29a31a0c3",
      "evidence": "The document highlights the limitations of current treatments and the potential benefits of Erasca's pipeline.",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet needs in cancer treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}